Recent trends in systemic psoriasis treatment costs

Archives of Dermatology

Volumn 146, Issue 1, 2010, Pages 46-54

  Beyer, Vivianne ^b,c,d   Wolverton, Stephen E ^a  

^a Departments of Dermatology and Clinical Affairs   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST VINCENT HOSPITAL   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; METHOXSALEN;

ARTICLE; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION COST; HUMAN; INJECTION SITE REACTION; LABORATORY TEST; LOADING DRUG DOSE; MAINTENANCE THERAPY; PATIENT MONITORING; PHOTOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PUVA; SYSTEMIC THERAPY; TREATMENT DURATION; TREND STUDY; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; OFFICE VISITS; PRESCRIPTION DRUGS; PSORIASIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 74549221523     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.319     Document Type: Article

References (42)

1. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with wide-spread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-139.
2. Fleischer AB Jr, Feldman SR, Rapp SR, et al. Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol. 1996;107(1):26-29.
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3, pt 1):401-407.
4. Callen JP, Krueger GG, Lebwohl M, et al; American Academy of Dermatology. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. 2003;49(5):897-899.
5. Simpson GL, Yelverton CB, Rittenberg S, Feldman SR. Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat. 2006;17(6):359-361.
6. Horn EJ, Fox KM, Patel V, Chiou C-F, Dann F, Lebwohl M. Are patients with psoriasis undertreated? results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57(6):957-962.
7. Patel V, Horn EJ, Lobosco SJ, Fox KM, Stevens SR, Lebwohl M. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J Am Acad Dermatol. 2008;58(6):964-969.
8. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408-414.
9. Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006;7(2):157-167.
10. About psoriasis: statistics. National Psoriasis Foundation Web site. http://www.psoriasis.org/netcommunity/learn-statistics. Accessed October 15, 2009.
11. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46(6):850-860.
12. Kaiser Family Foundation Prescription Drug Trends, May 2007 Fact Sheet. http://www.mchd-tx.org/documents/KaiserRxDrugTrends.pdf. Accessed July 13, 2008.
13. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
14. Lebwohl M, Ali S. Treatment of psoriasis, part 2: systemic therapies. J Am Acad Dermatol. 2001;45(5):649-661.
15. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J Dermatolog Treat. 2006;17(2):96-107.
16. Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol. 2005;53(1):73-75.
17. Red Book: Pharmacy's Fundamental Reference (Red Book Drug Topics). Montvale, NJ: Blackwell Publishing Limited; 2000-2008.
18. CPT code search. American Medical Association Web site. https://catalog.ama-assn.org/Catalog/cpt/cpt-search.jsp. Accessed October 19, 2009.
19. Centers for Medicare and Medicaid Services. Clinical Laboratory and Physician fee schedules. http://www.cms.hhs.gov/home/medicare.asp. Accessed July 7, 2008.
20. CPT code search. American Medical Association Web site 2008. https://catalog.ama-assn.org/Catalog/cpt/cpt-search.jsp?-requestid=74979. Accessed July 7, 2008.
21. Consumer Price Index detailed report (June 2008). US Department of Labor: Bureau of Labor Statistics Web site. http://www.bls.gov/cpi/cpid0806.pdf. Accessed October 19, 2009.
22. Nelson AA, Pearce DJ, Fleischer AB Jr, Balkrishnan R, Feldman SR. Costeffectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58(1):125-135.
23. Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003;4(9):1525-1533.
24. Papp KA. Monitoring biologics for the treatment of psoriasis. Clin Dermatol. 2008;26(5):515-521.
25. Huang W, Cordoro KM, Taylor SL, Feldman SR. To test or not to test?: an evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J Am Acad Dermatol. 2008;58(6):970-977.
26. Gencarelli DM. Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? NHPF Issue Brief. 2002;775(775):1-19.
27. Iglehart JK. Medicare and drug pricing. N Engl J Med. 2003;348(16):1590-1597.
28. Medicaid Drug Price Comparison: Average Sales Price to Average Wholesale Price. Office of Inspector General, Department of Health and Human Services Web site. June 2005. http://www.oig.hhs.gov/oei/reports/oei-03-05-00200.pdf. Accessed May 7, 2009.
29. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213(2):102-110.
30. Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004;20(12):1929-1936.
31. Opmeer BC, Heydendael VMR, de Borgie CAJM, et al. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol. 2004;140(6):685-690.
32. Employer Health Benefits, 2007 Annual Survey. Kaiser Family Foundation Web site. http://www.kff.org/insurance/7672/upload/76723.pdf. Accessed July 4, 2008.
33. Carroll J. When new drugs are costly, how high to raise copays? Manag Care. 2006;15(6):20-21, 25-26, 29-30.
34. Zuvekas SH, Cohen JW. Prescription drugs and the changing concentration of health care expenditures. Health Aff (Millwood). 2007;26(1):249-257.
35. The Public on Prescription Drugs and Pharmaceutical Companies. USA Today/ Kaiser Family Foundation/Harvard School of Public Health Web site. March 2008 Survey. http://www.kff.org/kaiserpolls/upload/7748.pdf. Accessed October 15, 2009.
36. Feldman SR, Fleischer AB Jr, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997;37(4):564-569.
37. News and Events: Total Cost to Develop a New Prescription Drug, Including Cost of Post-Approval Research, is $897 Million. Tufts Center for the Study of Drug Development Web site. May 13, 2003. http://csdd.tufts.edu/ NewsEvents/RecentNews.asp?newsid=29. Accessed October 15, 2009.
38. National Health Expenditure Web Tables, 1960-2006. Centers for Medicare and Medicaid Services Web site. http://www.cms.hhs.gov/NationalHealthExpendData/ downloads/tables.pdf. Accessed October 15, 2009.
39. Darst MA, Reddan J. Pharmacoeconomics. In: Wolverton S, ed. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia, PA: W.B. Saunders; 2007:991-1001.
40. Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2008;160(6):1264-1272.
41. Leon A, Nguyen A, Letsinger J, Koo J. An attempt to formulate an evidencebased strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. Expert Opin Pharmacother. 2007;8(5):617-632.
42. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(3):513-526.